FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  SMITH SANDFORD D						2. Issuer Name and Ticker or Trading Symbol  CYTOKINETICS INC [ CYTK ]  3. Date of Earliest Transaction (Month/Day/Year)  01/02/2015										k all app Direct Office	licable) for er (give title	able)		rson(s) to Issuer  10% Owner  Other (specify	
(Last)	`	,	Middle)		01/02	01/02/2013										belov	/)		below)		
280 EAST GRAND AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Application)						
(Street)																X Form filed by One Reporting Person					
	OUTH SAN RANCISCO CA 94080															Form filed by More than One Reporting Person					
(City)	(S	tate) (	Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/						Execution Date,				Transaction Dispos			rities Acc ed Of (D)		3, 4 Secur Benef Owne		rities F ficially (I d II		wnership m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									C	Code	v	Amoun	t (A)		rice	Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(IIISU: 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transact Code (In 8)			ative ities red sed 3,	6. Date Exercisabl Expiration Date (Month/Day/Year)			Amount of		of s ng	of De Se (In	rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		
					Code	v	(A)	(D)	Date Exerc	cisable	Exp	oiration te	Title	Amou or Numb of Share	er						
Non- Qualified Stock Option (right to buy)	\$7.37	01/02/2015			A		5,936		02/02	2/2015 <sup>(1)</sup>	01/	02/2025	Common Stock	5,93	6 \$	2.95 <sup>(2)</sup>	5,936		D		

## Explanation of Responses:

- 1. This option shall vest and become exercisable as to 5,936 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2016.
- 2. This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of 50% of an annual retainer of \$35,000.

By: Sharon A. Barbari For: Sandford D. Smith 01/05/2015

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.